UIPATH INC - CLASS A (PATH)

US90364P1057 - Common Stock

14.1691  +0.49 (+3.58%)

Fundamental Rating

5

PATH gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 279 industry peers in the Software industry. While PATH has a great health rating, there are worries on its profitability. PATH is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

3

1. Profitability

1.1 Basic Checks

PATH had positive earnings in the past year.
PATH had a positive operating cash flow in the past year.
In the past 5 years PATH always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: PATH reported negative operating cash flow in multiple years.

1.2 Ratios

Looking at the Return On Assets, with a value of -4.16%, PATH is in line with its industry, outperforming 50.90% of the companies in the same industry.
PATH has a Return On Equity of -6.13%. This is comparable to the rest of the industry: PATH outperforms 54.12% of its industry peers.
Industry RankSector Rank
ROA -4.16%
ROE -6.13%
ROIC N/A
ROA(3y)-11.83%
ROA(5y)-29.69%
ROE(3y)-16.3%
ROE(5y)-67.01%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

PATH has a better Gross Margin (83.98%) than 90.68% of its industry peers.
PATH's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for PATH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.57%
GM growth 5Y3.54%

More info and screens

8

2. Health

2.1 Basic Checks

PATH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PATH has more shares outstanding
There is no outstanding debt for PATH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 5.17 indicates that PATH is not in any danger for bankruptcy at the moment.
PATH has a Altman-Z score of 5.17. This is in the better half of the industry: PATH outperforms 62.72% of its industry peers.
PATH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 5.17
ROIC/WACCN/A
WACC11.9%

2.3 Liquidity

PATH has a Current Ratio of 3.60. This indicates that PATH is financially healthy and has no problem in meeting its short term obligations.
PATH has a better Current ratio (3.60) than 79.21% of its industry peers.
A Quick Ratio of 3.60 indicates that PATH has no problem at all paying its short term obligations.
PATH has a better Quick ratio (3.60) than 79.57% of its industry peers.
Industry RankSector Rank
Current Ratio 3.6
Quick Ratio 3.6

More info and screens

6

3. Growth

3.1 Past

PATH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.50%, which is quite impressive.
PATH shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.42%.
Measured over the past years, PATH shows a very strong growth in Revenue. The Revenue has been growing by 54.52% on average per year.
EPS 1Y (TTM)27.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55.56%
Revenue 1Y (TTM)20.42%
Revenue growth 3Y29.12%
Revenue growth 5Y54.52%
Sales Q2Q%10.07%

3.2 Future

Based on estimates for the next years, PATH will show a decrease in Earnings Per Share. The EPS will decrease by -0.74% on average per year.
Based on estimates for the next years, PATH will show a quite strong growth in Revenue. The Revenue will grow by 12.48% on average per year.
EPS Next Y-24.98%
EPS Next 2Y-8.95%
EPS Next 3Y-0.05%
EPS Next 5Y-0.74%
Revenue Next Year10.59%
Revenue Next 2Y10.84%
Revenue Next 3Y11.34%
Revenue Next 5Y12.48%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 27.78, PATH can be considered very expensive at the moment.
Based on the Price/Earnings ratio, PATH is valued a bit cheaper than the industry average as 75.99% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of PATH to the average of the S&P500 Index (28.96), we can say PATH is valued inline with the index average.
The Price/Forward Earnings ratio is 31.65, which means the current valuation is very expensive for PATH.
PATH's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. PATH is cheaper than 67.03% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.82, PATH is valued a bit more expensive.
Industry RankSector Rank
PE 27.78
Fwd PE 31.65

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of PATH indicates a rather cheap valuation: PATH is cheaper than 83.15% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 23.84
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.95%
EPS Next 3Y-0.05%

More info and screens

0

5. Dividend

5.1 Amount

PATH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UIPATH INC - CLASS A

NYSE:PATH (11/22/2024, 11:04:08 AM)

14.1691

+0.49 (+3.58%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.79B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 27.78
Fwd PE 31.65
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.16%
ROE -6.13%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 83.98%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.6
Quick Ratio 3.6
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)27.5%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-24.98%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)20.42%
Revenue growth 3Y29.12%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y